Alzheimer’s disease care is shifting from treating symptoms to focusing on early intervention and prevention. Advances in blood-based biomarkers, such as pTau181 and pTau217, now allow for earlier and less invasive diagnosis, enabling timely treatment and better clinical trial design. New disease-modifying drugs like lecanemab and donanemab show the greatest benefit when administered early, reinforcing the importance of proactive detection.
Researchers are also adopting a more systemic view of Alzheimer’s, exploring factors beyond the brain, including gut microbiome health, cholesterol metabolism, genetics, and mitochondrial function. Emerging tools like digital biomarkers and wearables, combined with updated diagnostic guidelines, empower clinicians and patients to act sooner. This evolving approach aims to move Alzheimer’s care toward prevention and personalized strategies, improving long-term outcomes and quality of life.
Use the link below to access the full article.
Download Document
